ARTICLE | Company News
Eisai sales and marketing update
August 3, 2015 7:00 AM UTC
Eisai launched Lenvima lenvatinib in the U.K. to treat patients with radioactive iodine refractory differentiated thyroid cancer. The compound is an inhibitor of multiple VEGF receptor tyrosine kinas...